In short
This article summarizes recent clinical trials investigating the safety and immunogenicity of vaccines containing recombinant Neisseria meningitidis group B NadA protein produced in E. coli cells by recombinant DNA technology and adsorbed on aluminum hydroxide. These vaccines are being studied for prevention of meningococcal disease caused by serogroup B strains in various populations, including healthy infants, adolescents, and adults with certain medical conditions. The trials aim to evaluate immune responses, dosing schedules, and safety profiles of these novel meningococcal B vaccines.
At a glance
- Populations Studied
- Healthy infants, adolescents, adults with asplenia, adults with generalized myasthenia gravis
- Vaccine Formulations
- MenABCWY, Bexsero, Trumenba, combination strategies
- Primary Outcomes
- Immunogenicity (hSBA titers), safety and tolerability
- Secondary Outcomes
- Persistence of antibodies, cellular immune responses, quality of life measures
- Safety Assessments
- Local and systemic reactions, adverse events, serious adverse events
- Dosing Schedules
- Various multi-dose regimens over periods of months to years
- Special Considerations
- Vaccination against other meningococcal serogroups, pneumococcal and Haemophilus influenzae type b
What is this vaccine?
This vaccine contains a recombinant Neisseria meningitidis group B NadA protein that is produced in E. coli cells using recombinant DNA technology. The protein is then adsorbed onto aluminum hydroxide. It is part of a combination vaccine that protects against meningococcal disease caused by several serogroups of N. meningitidis bacteria.
How does it work?
The vaccine works by stimulating the immune system to produce antibodies against the NadA protein found on the surface of meningococcal group B bacteria. If a vaccinated person is later exposed to these bacteria, their immune system can quickly recognize and destroy them before they cause disease.
What is it used for?
This vaccine component is used to help prevent invasive meningococcal disease caused by Neisseria meningitidis group B bacteria. Meningococcal disease can cause serious infections like meningitis (infection of the lining of the brain and spinal cord) and septicemia (blood infection).
How is it administered?
The vaccine is given as an intramuscular injection, typically in the upper arm or thigh. It is usually given as a series of doses according to a specific schedule, which may vary depending on age and other factors.
What do clinical trials show?
Clinical trials have evaluated the safety and effectiveness of this vaccine component in various populations:
- A study in healthy adolescents aged 11-14 years found that the vaccine produced an immune response against group B meningococcal strains.
- Another trial examined its use in infants as young as 2 months old, showing it could induce antibodies against multiple group B strains.
- Research has also looked at its effectiveness in adults with asplenia (absence of a functioning spleen), who are at higher risk for meningococcal disease.
Is it safe?
The vaccine has been shown to have an acceptable safety profile in clinical trials. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Headache
- Fatigue
- Muscle or joint pain
- Fever
Serious allergic reactions are rare but possible with any vaccine. The benefits of protection against meningococcal disease are considered to outweigh the risks for most people.
Who can receive this vaccine?
This vaccine is approved for use in various age groups, typically from infants to adults. However, it may be especially recommended for certain high-risk groups, including:
- People with certain medical conditions, like asplenia
- Laboratory workers routinely exposed to meningococcal bacteria
- People living in close quarters (e.g., college dormitories)
- Travelers to areas where meningococcal disease is common
A healthcare provider can determine if this vaccine is appropriate based on individual circumstances and risk factors.